AUTHORS
Daniel Landsburg, MD, Richard Thomas Maziarz, MD2, Amy Moskop, MS MD3, Leslie Popplewell, MD4, Scott R Solomon, MD5, Luke Mountjoy, DO6, Yongzi Yu7, Dheeraj Gianchandani8, Wendy Chiang, MD9, Stephen Lim10, Avishek Pal, MS11, Frederick L. Locke, MD12
AFFILIATIONS
1 Department of Medicine, University of Pennsylvania, Pennsylvania, United States
2 Center for Hematologic Malignancies, Oregon Health and Science University, Portland, Oregon, United States
3 Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, United States
4 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, United States
5 Northside Hospital Cancer Institute, Atlanta, United States
6 Colorado Blood Cancer Institute, Denver, United States
7 Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, United States
8 Novartis Healthcare Pvt Ltd, Hyderabad, India
9 Novartis Pharmaceuticals Corporation, East Hanover, United States
10 Novartis Pharmaceuticals Corporation, East Hanover, United States
11 Novartis Pharma AG, Basel, Switzerland
12 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, United States
ABSTRACT
Background:
Tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR)-T cell therapy is approved for adult patients (pts) with relapsed/refractory (r/r) follicular lymphoma (FL) after ≥2 lines of prior therapies. Long-term follow-up (LTFU) from the phase 2 ELARA trial (N=94) demonstrated durable clinical benefit at a median follow-up (mFU) of 61.0 months (mo), with a 4-year duration of response (DOR) of 61% and 5-year progression-free survival (PFS) of 46% in all pts; safety profile was manageable. French DESCAR-T registry data (mFU of 9.8 mo) showed robust real-world efficacy of tisagenlecleucel (N=113; overall response rate [ORR]: 98.2%, complete response rate [CRR]: 85.8%) in r/r FL. Preliminary efficacy and safety data (mFU: 6.7 mo) from the CIBMTR registry (N=64) have been reported previously; here we report the LTFU with updated clinical outcomes.
Methods:
Data were collected as a part of a noninterventional, prospective, longitudinal study using the Center for International Blood and Marrow Transplantation Research (CIBMTR) registry. All pts received commercial tisagenlecleucel between December 2022 and March 2026 in the US, Canada, Israel, and South Korea. Efficacy outcomes included ORR, CRR, PFS, DOR, and overall survival (OS). Key safety outcomes included incidence and severity of adverse events (AEs), including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias.
Results:
At data cutoff date (March 3, 2026), mFU was 28.5 mo, 147 patients with r/r FL received tisagenlecleucel infusion, of which 144 were evaluable for overall efficacy and safety. Median age at infusion was 66.7 (36.4-87.6) years and a majority had Eastern Cooperative Oncology Group performance status of 0-1 (94.6%). Thirty-four pts (23.1%) included in this study had grade 3A histology. Median number of prior therapies was 4 (range: 1-13), 15 pts (10.2%) received 1-2 prior lines of therapies, and 118 pts (80.3%) received ≥3 prior lines of therapies. Eighteen pts (12.2%) received prior hematopoietic cell transplantation. The median time between leukapheresis and CAR-T infusion was 35 (22.0-855.0) days and initial diagnosis to CAR-T infusion was 78.3 (11.4-388.7) mo.
In overall population (N=144), ORR was 93.8% (95% confidence interval [CI]: 88.5-97.1), and CRR was 83.3%. At data cutoff, 128 pts (88.9%) were alive, 24-mo DOR was 68.6% (95% CI: 58.2-76.9), 24-mo PFS was 61.2% (95% CI: 51.1-69.8), and 24-mo OS was 86.5% (95% CI: 77.7-92.0).
Anytime post-infusion, 98 pts (68.1%) had any grade CRS, of which 66 pts (45.8%) had grade 1, 27 pts (18.8%) had grade 2, 2 pts (1.4%) had grade 3, and 1 pt (0.7%) had grade 4 events. Twenty-seven pts (18.8%) had any grade ICANS, of which 11 pts (7.6%) had grade 1, 9 pts (6.3%) had grade 2, 4 pts (2.8%) had grade 3, and 2 pts (1.4%) had grade 4 events. Seventy-one pts (49.3%) had hypogammaglobulinemia. Beyond 12 mo post-infusion, 1 pt (1%) had tumor lysis syndrome, 18 pts (16.8%) had infections, and 9 pts (6.3%) had prolonged thrombocytopenia. Ten pts (6.9%) reported subsequent neoplasm and 16 pts (11.1%) died during study, none of which were treatment related (primary disease [n=11], infections [n=2], acute respiratory distress syndrome [n=1], organ failure [n=1], and not reported [n=1]).
Conclusions:
Real-world data from the largest reported cohort of pts with r/r FL treated with tisagenlecleucel demonstrates durable efficacy and manageable safety profile with LTFU. The outcomes were improved or consistent versus the pivotal ELARA trial and other real-world findings. These long-term findings support the clinical benefit of tisagenlecleucel as a treatment of choice for pts with r/r FL. Subgroup analyses based upon updated data from a longer follow-up will be presented at the conference.
DISCLOSURES
Daniel Landsburg, MD: Novartis, ADC Therapeutics - Honoraria; Novartis, ADC Therapeutics - Research Funding; AbbVie - Consultancy (Includes expert testimony); Abbvie, Novartis, ADC Therapeutics, Natera, Ipsen, Kite, Regeneron - Consultancy (Includes expert testimony)